Epiomic Epidemiology Series: Mild Cognitive Impairment Forecast in 14 Major Markets 2017–2027

October 2017 | 50 pages | ID: EF9B7611709EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Mild Cognitive Impairment in 14 Major Markets

Mild cognitive impairment (MCI) is a condition in which a person has problems with memory, language, executive function and visuospatial skills that are noticeable to others and can be observed in neuropsychological tests, but are not severe enough to interfere with everyday activities. MCI can further develop into dementia, retain its status, or sometimes revert to the normal cognitive status. A significant proportion of people with MCI later develop Alzheimer’s disease (AD).

This report provides the current prevalent population for Crohn’s disease across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, the two types of MCI (amnestic and non-amnestic), as well as ApoE genotypes in MCI patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global MCI market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of MCI and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific ApoE genotypes on MCI prevalent population.
• Identify sub-populations within MCI which require treatment.
• Gain an understanding of the specific markets that have the largest number of MCI patients.

Contents

CONTENTS

List Of Tables

LIST OF TABLES AND FIGURES

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR MILD COGNITIVE IMPAIRMENT

FEATURES OF MILD COGNITIVE IMPAIRMENT PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN ANALYSIS PUBLICATIONS

BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

PATIENT-BASED OFFERING

ONLINE PRICING DATA & PLATFORMS

REFERENCES

APPENDIX

LIST OF TABLES AND FIGURES

Table 1. Prevalence of mild cognitive impairment, total (000s)
Table 2. Prevalence of mild cognitive impairment, males (000s)
Table 3. Prevalence of mild cognitive impairment, females (000s)
Table 4. Patients with Amnestic MCI by Sex (000s)
Table 5. Patients with Non-amnestic MCI by Sex (000s)
Table 6. MCI Patients with ApoE 34 or 44 genotype, total (000s)
Table 7. MCI Patients with ApoE 22 or 23 genotype, total (000s)
Table 8. MCI Patients with ApoE 33 genotype, total (000s)
Table 9. Abbreviations and Acronyms used in the report
Table 10. USA Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 11. USA Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 12. Canada Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 13. Canada Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 14. France Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 15. France Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 16. Germany Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 17. Germany Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 18. Italy Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 19. Italy Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 20. Spain Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 21. Spain Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 22. UK Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 23. UK Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 24. Russia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 25. Russia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 26. Japan Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 27. Japan Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 28. China Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 29. China Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 30. India Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 31. India Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 32. Australia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 33. Australia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 34. Brazil Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 35. Brazil Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Table 36. Mexic  Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
Table 37. Mexic  Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)